413 related articles for article (PubMed ID: 29148406)
21. Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study.
Michelsen B; Sexton J; Wierød A; Bakland G; Rødevand E; Krøll F; Kvien TK
Semin Arthritis Rheum; 2020 Feb; 50(1):12-16. PubMed ID: 31358361
[TBL] [Abstract][Full Text] [Related]
22. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
23. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
24. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Oldfield V; Plosker GL
BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
[TBL] [Abstract][Full Text] [Related]
25. [RETROSPECTIVE DATA ANALYSIS OF THE PATIENTS WITH INFLAMMATORY JOINT DISEASES TREATED WITH GOLIMUMAB IN CROATIA].
Anić B; Babić-Naglić Ð; Grazio S; Kehler T; Kaliterna DM; Radoncić KM; Morović-Vergles J; Novak S; Prus V; Vlak T; Baresić M
Reumatizam; 2015; 62(1):12-9. PubMed ID: 27024887
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Retention Rate of Golimumab in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis in a Real-Life Setting.
Serrano-Benavente B; Valor L; Del Río Blasco T; Janta I; González Benítez R; Nieto-González JC; Martínez-Barrio J; Ovalles Bonilla JG; Ariza A; López-Longo FJ; Álvaro-Gracia JM; Monteagudo I; González-Fernández CM
J Clin Rheumatol; 2022 Jan; 28(1):e150-e155. PubMed ID: 33492028
[TBL] [Abstract][Full Text] [Related]
27. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides.
Biggioggero M; Favalli EG
Drug Dev Res; 2014 Nov; 75 Suppl 1():S38-41. PubMed ID: 25381973
[TBL] [Abstract][Full Text] [Related]
28. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.
Gomez-Reino JJ; Carmona L;
Arthritis Res Ther; 2006; 8(1):R29. PubMed ID: 16507128
[TBL] [Abstract][Full Text] [Related]
29. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
[No Abstract] [Full Text] [Related]
30. Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA.
Iannone F; Favalli EG; Caporali R; D'Angelo S; Cantatore FP; Sarzi-Puttini P; Foti R; Conti F; Carletto A; Gremese E; Cauli A; Ramonda R; Palermo A; Epis O; Priora M; Bergossi F; Frediani B; Salaffi F; Lopalco G; Cacciapaglia F; Marchesoni A; Biggioggiero M; Bugatti S; Balduzzi S; Carriero A; Corrado A; Bongiovanni S; Benenati A; Miranda F; Fracassi E; Perra D; Ferraccioli G; Lapadula G
Joint Bone Spine; 2021 Jan; 88(1):105062. PubMed ID: 32755721
[TBL] [Abstract][Full Text] [Related]
31. Golimumab improves socio economic and health economic parameters in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Krüger K; Burmester GR; Wassenberg S; Thomas MH
Curr Med Res Opin; 2020 Sep; 36(9):1559-1567. PubMed ID: 32609555
[TBL] [Abstract][Full Text] [Related]
32. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Furst DE; Kay J; Wasko MC; Keystone E; Kavanaugh A; Deodhar A; Murphy FT; Magnus JH; Hsia EC; Hsu B; Xu S; Rahman MU; Doyle MK
Rheumatology (Oxford); 2013 Oct; 52(10):1845-55. PubMed ID: 23838027
[TBL] [Abstract][Full Text] [Related]
33. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.
Kopp TI; Delcoigne B; Arkema EV; Jacobsen RK; Magyari M; Ibfelt EH; Locht H; Sellebjerg F; Cordtz RL; Jensen DV; Askling J; Dreyer L
Ann Rheum Dis; 2020 May; 79(5):566-572. PubMed ID: 32161058
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry.
Hernandez MV; Sanchez-Piedra C; Garcia-Magallon B; Cuende E; Manero J; Campos-Fernandez C; Martin-Domenech R; Del Pino-Montes J; Manrique S; Castro-Villegas MC; Ruiz-Montesinos D; Sanchez-Alonso F; Diaz-Gonzalez F; Cea-Calvo L; Gómez-Reino JJ;
Rheumatol Int; 2019 Mar; 39(3):509-515. PubMed ID: 30353269
[TBL] [Abstract][Full Text] [Related]
35. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures?
Nannini C; Cantini F; Niccoli L; Cassarà E; Salvarani C; Olivieri I; Lally EV
Arthritis Rheum; 2009 Jun; 61(6):801-12. PubMed ID: 19479708
[TBL] [Abstract][Full Text] [Related]
36. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
37. Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Campas-Moya C
Drugs Today (Barc); 2010 Jan; 46(1):13-22. PubMed ID: 20200692
[TBL] [Abstract][Full Text] [Related]
38. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.
Athanassiou P; Psaltis D; Georgiadis A; Katsifis G; Theodoridou A; Gazi S; Sidiropoulos P; Tektonidou MG; Bounas A; Kandyli A; Vounotrypidis P; Sakellariou GT; Vassilopoulos D; Huang Z; Petrikkou E; Boumpas D
Rheumatol Int; 2023 Oct; 43(10):1871-1883. PubMed ID: 37402886
[TBL] [Abstract][Full Text] [Related]
39. Golimumab (simponi) for inflammatory arthritis.
Med Lett Drugs Ther; 2009 Jul; 51(1316):55-6. PubMed ID: 19590489
[No Abstract] [Full Text] [Related]
40. Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database.
Bhoi P; Bessette L; Bell MJ; Tkaczyk C; Nantel F; Maslova K
BMJ Open; 2017 Sep; 7(9):e015872. PubMed ID: 28928177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
